SCHEMBL4178268

SCHEMBL4178268

Cc1cc2cc(N3CCNCC3)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 10/20 0.56
HTR3E A5X5Y0 5/20 0.54
HTR3B O95264 5/20 0.54
HTR3A P46098 5/20 0.54
HTR3D Q70Z44 5/20 0.54
HTR3C Q8WXA8 5/20 0.54
SIGMAR1 Q99720 5/20 0.54
HTR5A P47898 1/20 0.54
HTR1A P08908 4/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
CYP2A6 P11509 1/20 0.46
KEAP1 Q14145 1/20 0.46
AXL P30530 1/20 0.44
HTR7 P34969 4/20 0.43
OPRL1 P41146 1/20 0.43
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23010850 0.87 ADRB1 (0.56) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL9959961 0.87 CYP2A6 (0.49) CYP2A6KEAP1AXLHTT
SCHEMBL23010853 0.84 HTR3A (0.54) HTR3ACYP2A6KEAP1AXLHTT
SCHEMBL1486903 0.83 PDE3B (0.48) CYP2A6KEAP1AXLTP53CYP1A2
SCHEMBL7276571 0.76 HTR3E (0.57) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL22860344 0.75 ADRB1 (0.53) ADRB1HTR3EHTR3BHTR3AHTR3D
Bromide SCHEMBL11200399 0.75 HTR3E (0.55) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL15534306 0.75 HTR3A (0.69) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL14311061 0.74 MAPT (0.52) SIGMAR1HTT
Hydrochloric Acid SCHEMBL15534114 0.73 HTR3A (0.67) ADRB1HTR3EHTR3BHTR3AHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021030620-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC. (US) 2021-02-18 WO disclosed
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED 2009-03-19 US disclosed
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders GLAXO GROUP LIMITED (GB) 2006-11-23 US disclosed
EP-1562917-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED (GB) 2005-08-17 EP disclosed
WO-2004046124-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders XDH, CYP4X1, PDHX ADRB1 359/4885HTR3E 200/4885HTR3B 138/4885
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS XDH, CYP4X1, PDHX ADRB1 1042/4885HTR3E 550/4885HTR3B 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.